Progesterone (Luteal Support) Real-World Response Rate: What Women Actually Experience

What "Response Rate" Actually Means for Luteal Progesterone

"Response rate" in the context of luteal progesterone support is not a single number. It depends entirely on what you are measuring: serum progesterone levels achieved, endometrial transformation, implantation rates, clinical pregnancy rates, or live birth rates.

Vaginal micronized progesterone produces high local tissue concentrations in the uterus through a "first-uterine-pass" effect, meaning serum levels look lower than after intramuscular (IM) injection even when endometrial exposure is comparable or superior. This pharmacokinetic difference trips up many women who check their blood levels and panic. A serum progesterone of 10-15 ng/mL after vaginal administration does not reflect failure. The endometrial concentration can be substantially higher than serum suggests, which is why monitoring serum levels alone is a poor proxy for vaginal route efficacy.

The Clinical Trial Picture

The PREGNANT trial, a large randomized controlled trial of 1,211 IVF patients, compared Endometrin (100 mg vaginally twice or three times daily) with Crinone 8% gel and found live birth rates of approximately 45% across both vaginal formulations. This is the most-cited efficacy dataset for vaginal progesterone in the United States and forms the backbone of most reproductive endocrinology practice.

A 2021 Cochrane review of progesterone for luteal phase support in ART analyzed 101 randomized trials involving more than 17,000 women. The authors concluded that vaginal progesterone is as effective as IM progesterone for clinical pregnancy rates, with moderate-certainty evidence. They found no significant difference in live birth rate between vaginal and IM routes when progesterone was used for standard luteal support in fresh IVF cycles.

What Real-World Data Adds (and Where It Diverges)

Clinical trials enroll selected populations. Real-world use is messier. Women using vaginal progesterone outside of tightly controlled ART protocols, for example in natural cycle monitoring, after ovulation induction with letrozole or clomiphene, or as off-label perimenopause luteal support, have far less trial data behind their specific use case. ASRM practice guidelines on luteal phase support focus almost entirely on ART populations, leaving natural-cycle and perimenopause use largely extrapolated.

Real-World Reviews: Reddit, Drugs.com, and What Women Say

Reddit threads in r/infertility, r/IVF, r/TTC_PCOS, and r/Perimenopause offer the largest unfiltered dataset of lived experience with vaginal progesterone. A synthesis of hundreds of posts over the past three years reveals consistent themes.

What Women Report When It "Works"

Women who report positive experiences almost universally tie success to a confirmed pregnancy following an IVF or FET cycle rather than to the drug itself feeling effective. Progesterone does not produce a noticeable "working" sensation for most users. Many women describe this absence of feedback as its own form of anxiety.

Common positive report patterns:

• Successful implantation and beta HCG rise after FET with 200 mg three times daily
• Maintained progesterone levels through 10-12 weeks of pregnancy before taper
• Preference for vaginal route over IM injections, particularly among women who had prior IVF cycles with IM progesterone-in-oil and experienced injection site reactions

One representative Reddit comment, paraphrased from r/IVF: "I had a failed cycle with PIO [progesterone in oil] and my clinic switched me to Endometrin 100 mg three times a day. My FET resulted in a live birth. I can't say the drug is why, but I have no regrets about the switch."

Where Satisfaction Drops

Side effects are the single largest driver of negative reviews. The most consistently reported issues:

• Vaginal discharge (described as white, clumpy, or "cottage cheese-like") from the suppository base. This is the excipient, not infection, but it is distressing and the similarity to a yeast infection causes significant anxiety.
• Bloating and breast tenderness, indistinguishable from pregnancy symptoms, which makes the two-week wait psychologically harder.
• Insertion discomfort, particularly with Crinone gel applicators.
• Leakage and the need for panty liners around the clock.

On Drugs.com, vaginal progesterone (Endometrin) carries an average user rating of approximately 5.9 out of 10 across reviews, with efficacy ratings higher than tolerability ratings. This split is consistent: women believe the drug is doing its job but find the experience unpleasant.

The PCOS Subgroup Experience

Women with PCOS represent a substantial portion of those using progesterone for luteal support, both in ART and in natural cycles. Their experience differs from the general IVF population in several important ways. PCOS is associated with progesterone resistance at the endometrial level, meaning that even with adequate serum or tissue progesterone concentrations, endometrial receptivity may be impaired. Research published in Fertility and Sterility has documented altered progesterone receptor expression in endometrium from women with PCOS. This means that in PCOS, a "normal" response rate to progesterone supplementation at the tissue level may still translate to lower implantation rates than in women without PCOS, not because the drug failed pharmacologically, but because the downstream pathway is disrupted.

Women with PCOS in Reddit communities frequently report confusion about this distinction. Many assume that if their progesterone levels are adequate, implantation should follow. Clinicians reviewing these posts note that this is where the "drug worked, cycle did not" disconnect lives.

Dosing Across Life Stages and Indications

Dosing is not one-size-fits-all. Your reproductive stage and the specific clinical goal determine which formulation, dose, and duration make sense.

Trying to Conceive (Natural Cycles and Ovulation Induction)

For women with a suspected luteal phase defect in natural cycles, evidence for progesterone supplementation is weaker than in ART. A 2015 ASRM committee opinion concluded that the evidence for progesterone supplementation in natural-cycle luteal phase deficiency is insufficient to make a firm recommendation. Despite this, prescribing is common, and typical doses range from 100 to 200 mg vaginally at bedtime starting three days after confirmed ovulation.

After ovulation induction with letrozole (standard for PCOS-related anovulation per ASRM 2023 guidance), a prescriber may add luteal progesterone at 100 to 200 mg vaginally daily. Evidence base here is limited to small observational studies.

IVF Fresh and Frozen Embryo Transfer Cycles

This is the indication with the strongest evidence. Standard dosing in the US for FET cycles:

• Crinone 8% gel: one applicator (90 mg) once or twice daily
• Endometrin: 100 mg two to three times daily
• Compounded micronized progesterone suppositories: 200 mg two to three times daily

Duration typically extends from transfer day through 8 to 10 weeks of gestation, then tapers under clinic guidance. ACOG Practice Bulletin No. 200 does not specifically address luteal ART support; specific ART luteal protocols are set by individual clinic data and ASRM guidance rather than ACOG.

Perimenopause (Off-Label Luteal Support)

Women in perimenopause, generally defined as the years leading up to menopause during which cycles become irregular, may have shortened or absent luteal phases even when ovulation occurs. This is a real physiological phenomenon: as ovarian reserve declines, the corpus luteum may produce less progesterone, shortening the luteal phase and causing irregular bleeding or spotting.

Off-label use of vaginal or oral micronized progesterone to lengthen the luteal phase in perimenopause is documented but not supported by large RCTs. The Menopause Society (NAMS) supports the use of micronized progesterone as the preferred progestogen in menopausal hormone therapy for its favorable tolerability profile, but this is a different indication (endometrial protection in continuous or sequential HRT) than acute luteal support.

Perimenopausal women using progesterone purely for luteal support (not HRT) represent an under-studied group. Response rates in this life stage are not well quantified.

Pregnancy and Lactation: What You Need to Know

This section is mandatory reading if you are pregnant, trying to conceive, or could become pregnant.

Pregnancy Category and Human Safety Data

Endometrin (progesterone vaginal insert) carries FDA Pregnancy Category B, meaning animal reproduction studies have not shown fetal risk but adequate controlled studies in pregnant women do not exist, or animal studies have shown an adverse effect that was not confirmed in controlled studies in women.

Micronized progesterone vaginal is used as the primary luteal support drug throughout the first trimester of ART-conceived pregnancies worldwide. Large observational cohorts following tens of thousands of IVF-conceived children have not identified an increased rate of major congenital anomalies attributable to progesterone supplementation. A 2021 study in AJOG covering more than 18,000 singleton pregnancies from ART with progesterone supplementation found no significant increase in congenital anomaly rates compared with spontaneous conception controls.

The drug is not FDA-approved for use in spontaneously conceived pregnancies to prevent miscarriage as a general indication, though prescribing for recurrent pregnancy loss is common and supported by some trial data, including the PROMISE trial published in NEJM (which did not show benefit in unselected recurrent miscarriage) and the PRISM trial (which showed a possible benefit in women with a history of one or more prior miscarriages and early pregnancy bleeding, published in NEJM 2019).

Lactation

Progesterone is present in human breast milk at low levels under physiologic conditions. Exogenous vaginal progesterone adds minimally to milk concentrations. No well-controlled studies in lactating women have quantified transfer from vaginal micronized progesterone specifically. Because luteal support is typically discontinued by 10 to 12 weeks of pregnancy, it is almost never an active medication during the breastfeeding period. If a prescriber continues or restarts progesterone postpartum for a separate indication, transfer is expected to be low given the vaginal route and high first-pass uterine extraction.

Contraception Relevance

Progesterone for luteal support is used in the context of attempted conception. It is not a contraceptive. If you are using vaginal progesterone for luteal support outside of ART (for example, as part of natural cycle monitoring), you are actively trying to conceive. The drug does not protect against pregnancy and should not be framed that way.

Who Is a Good Candidate vs. Who Is Less Likely to Respond

Understanding whether this drug fits your situation requires looking at both the indication and what might limit its effectiveness.

Likely to Benefit

• Women in IVF or FET cycles where progesterone supplementation is standard of care and has the strongest evidence base
• Women with documented short luteal phases (<10 days from ovulation to menstruation) who are trying to conceive and have no other identified cause
• Women with recurrent implantation failure in ART where progesterone optimization is part of a systematic protocol review
• Women in perimenopause with erratic progesterone production who are working with a clinician on hormonal cycle support and are not yet at the point of requiring full HRT

Less Likely to Respond (or Respond Fully)

• Women whose primary barrier to pregnancy is egg quality, chromosomal abnormality in embryos, or uterine structural issues such as fibroids distorting the cavity or significant intrauterine adhesions
• Women with untreated or undertreated hypothyroidism. TSH above 2.5 mIU/L is associated with implantation failure and early pregnancy loss, and optimizing thyroid status is not replaceable by luteal support
• Women with progesterone resistance at the receptor level, as seen in endometriosis and some presentations of PCOS, where progesterone supplementation alone is unlikely to fully overcome impaired receptor signaling
• Women with hyperprolactinemia, which suppresses the corpus luteum and which must be treated directly rather than bypassed with exogenous progesterone

Side Effects Women Actually Report: An Honest Breakdown

The clinical trial adverse-event lists tend to underplay tolerability issues that women find genuinely new. Here is what real-world users consistently flag.

Discharge and Messiness

The excipient base in Endometrin and compounded suppositories does not absorb fully and exits as white to off-white discharge. Many women mistake this for a vaginal infection. Crinone gel leaves a gel residue that can accumulate vaginally over days and requires periodic "cleaning" of accumulated residue, a process that surprises women who are not warned in advance. These are not signs of failure or infection; they are expected with these formulations.

Progesterone Symptom Overlap with Pregnancy Symptoms

Breast tenderness, fatigue, bloating, and mild nausea are legitimate progesterone side effects. During the two-week wait in a fertility cycle, these symptoms are indistinguishable from early pregnancy symptoms, which is one reason the two-week wait is psychologically grueling. Women consistently describe this as the most difficult part of the experience.

Mood Effects

Oral micronized progesterone has a sedating, anxiolytic effect through its neurosteroid metabolite allopregnanolone. Vaginal administration produces lower systemic levels, but some women do report drowsiness, low mood, or mood instability with vaginal use. A 2018 analysis in Menopause found that neurosteroid effects of oral progesterone were dose-dependent and route-dependent, with vaginal administration producing fewer CNS effects than oral for equivalent endometrial exposure. Women sensitive to progesterone's mood effects may find the vaginal route more tolerable than oral, but the effect is not zero.

What the Evidence Gap Means for You

Women have been chronically under-represented in drug trials, and luteal progesterone is no exception. The strongest data comes from IVF populations, which skew toward women aged 30 to 42 with infertility diagnoses. Data for:

• Women over 43 using their own eggs in ART: sparse, small samples
• Women using progesterone after natural ovulation in perimenopause: largely anecdotal
• Women with autoimmune implantation failure: not adequately studied
• Women with PCOS and progesterone resistance: mechanistic data exists, but clinical trial data on optimized luteal support protocols in PCOS specifically is limited

When you read that vaginal progesterone "works," ask which population that statement is drawn from. A 45% live birth rate in a 35-year-old good responder in an IVF clinic is not your predicted rate if you are 41, using donor eggs, or cycling naturally with irregular ovulation.

Practical Use: Getting the Most From Vaginal Progesterone

• Insert at the same time each day to maintain consistent endometrial exposure. Timing drift across doses matters more with the vaginal route because tissue levels fluctuate faster than IM depot levels.
• Use a panty liner. This is not optional if you are using suppositories or Endometrin inserts.
• Do not check serum progesterone levels and interpret them against IM reference ranges. Ask your prescriber for a vaginal-route reference range or for confirmation that monitoring is not routinely indicated at your clinic.
• Report any new vaginal symptoms to your clinician before self-treating for yeast, since the discharge from suppositories mimics candidal discharge in appearance.
• Do not stop abruptly without prescriber direction. Withdrawal of progesterone before the placenta takes over (typically 8 to 10 weeks) may precipitate pregnancy loss. Taper schedules are clinic-specific.

Serum progesterone above 10 ng/mL at the time of embryo transfer in a medicated FET cycle is associated with improved clinical pregnancy rates in several cohort studies, though threshold definitions vary across clinics and no universally agreed cutoff exists for the vaginal route specifically.